Relay Therapeutics Inc (RLAY) Q4 2025 Earnings Call Transcript

Why It Matters

The earnings beat and rapid Acute Care adoption de‑risk Heron’s balance sheet and position it for higher‑margin, scalable growth in a competitive supportive‑care market.

Key Takeaways

• Adjusted EBITDA $14.7M, beating guidance.
• Acute Care revenue up 57% YoY, ZYNRELEF +48%.
• Permanent J‑Codes granted for ZYNRELEF and APONVIE.
• CrossLink IGNITE program expands distributor engagement.
• Oncology revenue down 7.8% due to SUSTOL wind‑down.

Pulse Analysis

Heron Therapeutics (NASDAQ: HRTX) closed 2025 with $155 million in net product sales, driven primarily by its Acute Care portfolio. The company’s lead injectable, ZYNRELEF, posted a 48% year‑over‑year revenue jump, while APONVIE nearly doubled, reflecting broader hospital adoption of non‑opioid postoperative pain and anti‑nausea solutions. Two permanent J‑Codes—J0668 for ZYNRELEF and J8502 for APONVIE—were secured, eliminating billing uncertainty and aligning with the federal NOPAIN Act, which encourages reimbursement for opioid‑sparing therapies. These coding milestones reduce administrative friction and improve payer confidence, a critical lever in the highly regulated supportive‑care market.

Heron’s commercial engine was turbocharged in 2025 through the CrossLink IGNITE program, an incentive‑based partnership that sharpened distributor focus on high‑potential accounts. Coupled with the rollout of a vial access needle (VAN) that simplifies drug preparation, the initiative lifted ZYNRELEF’s Q4 net sales to $12.5 million, a 33% quarter‑over‑quarter rise. The company also announced a dedicated APONVIE sales team and highlighted its inclusion in the Fifth Consensus Guidelines for postoperative nausea and vomiting, a credential that typically accelerates formulary adoption. Management projects 2026 net product sales of $173‑$183 million, acknowledging that expanded field capacity may temper short‑term EBITDA growth but is expected to generate outsized top‑line momentum.

Despite Acute Care strength, Heron’s Oncology supportive‑care franchise slipped 7.8% to just over $105 million as the planned SUSTOL wind‑down progressed, underscoring the need for diversification. The firm is advancing a prefilled syringe presentation for ZYNRELEF, with stability batches placed in Q4 and a regulatory filing anticipated for mid‑ to late‑2027, representing a potential next‑generation growth catalyst. Additionally, the completion of a refinancing transaction removed a lingering capital‑structure overhang, delivering a “meaningful derisking event” and freeing cash for the 2026 commercial expansion. Investors should monitor reimbursement policy shifts, competitive pressures on CINVANTI, and the timing of the syringe approval, all of which will shape Heron’s trajectory toward sustained profitability.